A decrease in target lesion tumor burden was observed in 44 of 71 (62%) response-evaluable patients with available percentage change values (Extended Data Fig. 7 and Supplementary Fig. 14), with a confirmed ORR across this diverse group of refractory HER2+ tumor types of 19% (14/72; 95% CI: 11–30), regardless of PD-L1 status at baseline (Extended Data Fig. 8a). The gene discussed is ERBB2; the disease is neoplasm.